1 |
<p align="center"><b>CEO of PLIVA opens new Development Center in AWD.pharma</b></p> |
2 |
<p><i>Dresden, 2 October 2001</i></p> |
3 |
<p>PLIVA's CEO Zeljko Covic opened the Pharmaceutical Development Center in AWD.pharma. |
4 |
The Development Center is directly integrated with the production area, which |
5 |
grants the interaction between development and manufacturing. At the new Development |
6 |
Center, which was an investment worth approximately EUR 3 million, 26 employees |
7 |
will work in laboratories and pilot facilities.</p> |
8 |
<p>The new Development Center in Dresden fits into the development strategy of |
9 |
PLIVA, a company with 65 years of successful research and development.</p> |
10 |
<p>The opening ceremony led by top executives of the corporation from Zagreb was |
11 |
an expression of the integration of AWD.pharma and the parent company.</p> |
12 |
<p>"AWD.pharma, additionally strengthened by the Development Center, offers new |
13 |
values to PLIVA's big family. This milestone will also contribute to our plans |
14 |
to increase our presence on the demanding German pharmaceutical market. But |
15 |
we will not stop there - our goal is the large European Union market. That is |
16 |
why every advancement of AWD.pharma at the same time strengthens PLIVA and, |
17 |
consequently, fosters the achievement of our objectives", stressed PLIVA's CEO |
18 |
Zeljko Covic at the opening ceremony of the Development Center.</p> |
19 |
<p> <b>PLIVA</b><br> |
20 |
Founded in 1921, PLIVA is celebrating its 80th anniversary as the leading pharmaceutical |
21 |
company in Central and Eastern Europe, dedicated to achieving its vision to |
22 |
be a pharmaceutical company bringing superior and innovative solutions to customer |
23 |
needs, by competing in the global market, which will enable its stable growth |
24 |
and development in the future.<br> |
25 |
AWD.pharma became a part of PLIVA in July 2001.<br> |
26 |
AWD.pharma develops, manufactures, markets and distributes high quality generic |
27 |
drugs under its own trademarks.</p> |
28 |
<p>For additional information, please contact:<br> |
29 |
Bernhard Sorms<br> |
30 |
E-mail: <a href="mailto:Bernhard.Sorms@awd-pharma.com">Bernhard.Sorms@awd-pharma.com</a></p> |